Visiongain Publishes Amino Acid Metabolism Disorders Treatment Market Report to 2031

12 March 2021
Pharma

Visiongain has published a new report on Amino Acid Metabolism Disorders Treatment Market Report to 2031: Forecasts by Product Type (Folic Acid, Vitamin B6&ampB12, Arginine, Thiamine, Vitamin D, Betaine, Sapropterin Dihydrochloride, and Carglumic Acid), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Stores) PLUS COVID-19 Recovery Scenarios.

Global Amino Acid Metabolism Disorders Treatment market size is projected to reach US$ XX Million in 2021 and is expected to display strong revenue growth through to 2031.

COVID-19 Impact on Amino Acid Metabolism Disorders Treatment Market
COVID-19 outbreak has affected over 200 countries globally. The pandemic has negatively impacted all the economies and industries. Similarly, the global amino acid metabolism disorders treatment market is estimated to take a hit. The target industry is now facing challenges to manage the interrupted demand and supply of medical components. Also, unpredictable and disturbing supply chain activities and the unavailability of human resources are anticipated to impact the target industry growth. Hence, the overall COVID-19 impact is expected to continue to moderate for the global key players operating in the industry.

Market Drivers

Rising Prevalence of Chronic Diseases
Rising incidence and prevalence of Familial hypercholesterolemia, Gaucher disease, Hunter syndrome, Krabbe disease, Maple syrup urine disease, Metachromatic leukodystrophy, Mitochondrial encephalopathy, lactic acidosis, stroke-like episodes (MELAS), and Niemann-Pick are expected to be major driving factors for the growth of the amino acid metabolism disorders treatment market during the forecast period. According to the National Institutes of Health, approximately 1 in 185,000 infants suffer from maple syrup urine disease globally. The disease arises much more often in the Old Order Mennonite people, with an estimated occurrence of around 1 in 380 newborns.

Thereby, the rising high prevalence of chronic disorders demands proper treatment management to maximize patient outcomes. In turn, it is projected to attain substantial growth for the amino acid metabolism disorders treatment market in the given time frame.

Growing Awareness and Rising Spending in the Research & Development
The key factors pushing the growth of the amino acid metabolism disease treatment market are the prevalence of amino acid metabolism disorders around the world. Besides, increased disposable income in developing countries such as India and China and rising healthcare spending along with the growing acceptance of non-invasive treatment are also accelerating the growth of the amino acid metabolism disorders treatment market. Moreover, rising awareness among the population and the development of healthcare infrastructure are contributing to the target industry growth.

The rising research & development activities to develop ground-breaking and effective treatments for amino acid metabolism disorders are fuelling the target industry growth. In recent times, numerous methods have been advanced to help in the initial diagnosis and observation of amino acid metabolism disorders and related complications. These developments in amino acid metabolism disorders diagnosis have increased the number of patients detected with this illness and give better treatment options. Hence, it is expected to attain a noteworthy growth rate over the forecast period.

Market Opportunities

Rapidly Increasing Health Care Expenditure
Rising health expenditure per capita is accredited towards factors such as improving economic conditions in developing countries, greater access to competent emergency treatment. For instance, healthcare spending has increased drastically in the U.S. in the past few decades. As per the Journal of the American Medical Association (JAMA), healthcare expenditure in the U.S. upsurge near a trillion dollars between 1996 and 2015. The association told that healthcare expenditure in the U.S. during 2017 was around $3.5 trillion, i. e, $11,000 per person. These expenditures are projected to be $6 trillion—approximately $17,000 per person by 2027.

Competitive Landscape
Key players operating in the global Amino Acid Metabolism Disorders Treatment market are Civentichem, LLC, Ltd., GlaxoSmithKline PLC, AMINO GmbH, Pfizer, Inc., Recordati S.p.A., Merck KGaA, Koninklijke DSM N.V., Shine Star (Hubei) Biological Engineering Co., Sanofi, and Kyowa Hakko Kirin Co., Ltd.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes 3D Printing for Healthcare Market Report 2021-2031

The growing use of this technology in many applications such as transplantation, drug delivery, 3D printed organs, and many others in the healthcare industry is one of the key drivers in the global 3D Printing in Healthcare Market.

02 August 2021

Read

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

Read

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever